A Liquid Biopsy-based Multicancer Early Detection Test May Detect Early-stage Disease and Low DNA-shedding Cancers
The multicancer early detection platform was developed based on methylation of cell-free DNA ORLANDO, Fla. – A liquid biopsy-based...
Search/Filter
Loading...
Adjuvant Treatment With Atezolizumab and Bevacizumab May Delay Recurrence After Surgical Resection in Patients With Liver Cancer
ORLANDO, Fla. – Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma...
Adding a Personalized mRNA Cancer Vaccine to Immunotherapy May Prolong Recurrence-free Survival in Patients With High-risk Melanoma
Clinical benefit was independent of patients’ tumor mutational burden ORLANDO, Fla. – mRNA-4157/V940, a personalized mRNA-based cancer vaccine,...
First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers
ORLANDO, Fla. – The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated...
Durvalumab-based Treatment Before and After Surgery Improved Outcomes for Patients With Resectable Non-small Cell Lung Cancer
Patients treated with the durvalumab-based regimen before and after surgery in the AEGEAN trial had a 32% reduction in...
Breast-conserving Therapy May be a Treatment Option for Some Patients with Multiple Breast Lesions
SAN ANTONIO – Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy...
Genetic Profiling May Identify Patients with Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-conserving Surgery
SAN ANTONIO – Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had...
Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...
Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term Outcomes for Patients with Metastatic Breast Cancer
SAN ANTONIO – The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine...